Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | SLC18A2 | Q05940 | 9/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23142670 | 1.00 | HTR1A (0.75) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL23118013 | 0.95 | HTR1A (0.79) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018923 | 0.90 | HTR1A (0.78) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018919 | 0.90 | HTR1A (0.78) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018921 | 0.90 | HTR1A (0.78) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL23117968 | 0.89 | HTR1A (0.77) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL22579521 | 0.89 | HTR1A (0.75) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL23117987 | 0.89 | HTR1A (0.75) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL23118004 | 0.89 | HTR1A (0.75) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL23118014 | 0.88 | SLC18A2 (0.76) | HTR1ATBXA2RPTGS1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087191-A1 | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF | DISPERSOL TECHNOLOGIES, LLC | 2021-03-25 | — | — | US | claimed |
| US-20210087191-A1 | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF | DISPERSOL TECHNOLOGIES, LLC | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087191-A1 | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF | SLC6A2, SLC18A2, SLC6A3 | HTR1A 35/4885TBXA2R 831/4885PTGS1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.